Table 2.
Laboratory characteristics and comparisons corresponding to the visit corresponding to 60 months in individuals with HIV, HIV-HBV co-infection with positive HBsAg and individuals with HIV-HBV and HBsAg loss.
| Laboratory characteristics |
HIV group (N = 111) |
HIV-HBV group (N = 62) |
HIV-HBV with HBsAg loss (N = 39) |
P -value |
|---|---|---|---|---|
| Median Lymphocytes, IQR (cells/μL) | 2,220 (1,900, 2,797) | 1,935 (1,540, 2,545) | 2,140 (1,820, 2,760) | 0.060 |
| Median Thrombocytes, IQR (cells/μL) | 2,48,500 (1,95,250, 2,73,500) | 2,14,000 (1,53,250, 2,72,000) | 2,62,000 (1,99,000, 3,01,000) | 0.016 |
| Median INR, IQR (IU/L) | 0.97 (0.92, 1.04) | 0.98 (0.95, 1.04) | 0.99 (0.96, 1.04) | 0.363 |
| Median AST, IQR (IU/L) | 26 (20, 34) | 33 (25, 41.5) | 28 (23, 36) | 0.061 |
| AST > ULN* (%) | 10 (9%) | 8 (12.9%) | 4 (10.2%) | 0.710 |
| Median ALT, IQR (IU/L) | 29 (21, 39) | 36 (24, 53) | 33 (23, 40) | 0.322 |
| ALT > ULN* (%) | 16 (14.4%) | 7 (11.3%) | 2 (5.1%) | 0.238 |
| Median ALP, IQR (IU/L) | 72 (57, 89) | 71 (52, 94) | 63.5 (54, 87) | 0.614 |
| Median GGT, IQR (IU/L) | 32 (20, 51) | 29 (22, 39) | 24 (16, 33) | 0.316 |
| Total bilirubin >2 mg/dl (%) | 4 (3.6%) | 2 (3.2%) | 1 (2.5%) | 0.971 |
| Median serum glucose, IQR (mg/dl) | 94 (87, 104) | 92 (87, 99) | 91 (80, 106) | 0.210 |
| Serum cholesterol >200 mg/dl (%) | 52 (46.8%) | 19 (30.64%) | 12 (30.76%) | 0.262 |
| Median serum cholesterol, IQR (mg/dl) | 204 (179, 235) | 192 (175, 218) | 183 (148, 214) | 0.038 |
| Tryglicerides >150 mg/dl (%) | 45 (40.5%) | 17 (27.42%) | 11 (28.20%) | 0.473 |
| Median tryglicerides, IQR (mg/dl) | 141 (98, 211) | 125 (90, 193) | 130 (82, 230) | 0.554 |
| HDL-Cholesterol <50 mg/dl (%) | 18 (16.2%) | 16 (25.8%) | 10 (25.64%) | 0.652 |
| Median HDL-Cholesterol, IQR (mg/dl) | 48 (37, 55) | 41 (33, 57) | 43 (38, 57) | 0.513 |
| Median serum proteins, IQR (g/dl) | 7.75 (7.4, 8.3) | 7.85 (7.4, 8.2) | 7.6 (7.3, 8.05) | 0.625 |
| Median Albumin, IQR (g/dl) | 4.82 (4.5, 5.2) | 4.96 (4.59, 5.4) | 4.8 (4.3, 5.2) | 0.318 |
| Median AFP, IQR (ng/ml) | 0.8 (0.17, 3.95) | 1.2 (0.5, 4.1) | 0.4 (0.2, 0.4) | 0.339 |
| Detectable plasma HIV RNA (%) |
39 (35.1%) | 22 (42.3%) | 8 (20.51%) | 0.107 |
| Median plasma log10 HIV RNA, IQR (copies/ml) | 1.47 (1.3, 1.72) | 1.63 (1.32, 3.06) | 1.7 (1.3, 2.45) | 0.160 |
| CD4 T cells <200 cells/mm3 (%) |
1 (0.9%) | 3(4.83%) | 1 (2.56%) | 0.269 |
| CD4 T cells <500 cells/mm3 (%) |
23 (20.72%) | 19 (30.64%) | 10 (25.64%) | 0.308 |
| Median CD4 T cell count, IQR (cells/mm3) | 732 (521, 927) | 596 (450, 827) | 641 (429, 810) | 0.036 |
Continuous variables are represented using the median and IQR, while categorical variables are displayed using the number (%) of cases.
*
ULN – upper limit of normal (according to the laboratory kit and producer recommendations).